Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.

When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.

Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.

Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.

Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.

Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.

Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.

Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.